Blair William & CO Eagle Pharmaceuticals, Inc. Transaction History

Blair William & CO

$33.4 Billion
Q3 2024

A detailed history of Blair William & CO transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Blair William & CO holds 12,952 shares of EGRX stock, worth $6,735. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,952

Previous 13,100 1.13%

Holding current value

$6,735

Previous $73,000 34.25%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$3.71 - $6.07 $549 - $898	-148 Reduced 1.13%	12,952 $48,000
Q2 2024 Aug 12, 2024	SELL	$3.34 - $5.6 $3,507 - $5,880	-1,050 Reduced 7.42%	13,100 $73,000
Q1 2024 May 09, 2024	SELL	$4.26 - $6.51 $13,695 - $20,929	-3,215 Reduced 18.51%	14,150 $74,000
Q4 2023 Feb 12, 2024	SELL	$4.63 - $15.21 $23,543 - $77,342	-5,085 Reduced 22.65%	17,365 $90,000
Q3 2023 Nov 09, 2023	SELL	$15.21 - $22.88 $27,758 - $41,756	-1,825 Reduced 7.52%	22,450 $354,000
Q2 2023 Aug 11, 2023	SELL	$17.74 - $31.87 $41,688 - $74,894	-2,350 Reduced 8.83%	24,275 $471,000
Q1 2023 May 12, 2023	SELL	$25.06 - $34.09 $314,427 - $427,727	-12,547 Reduced 32.03%	26,625 $755,000
Q4 2022 Feb 10, 2023	SELL	$24.98 - $39.77 $79,561 - $126,667	-3,185 Reduced 7.52%	39,172 $1.14 Million
Q2 2022 Aug 10, 2022	SELL	$41.26 - $51.35 $825 - $1,027	-20 Reduced 0.05%	42,357 $1.88 Million
Q1 2022 May 13, 2022	SELL	$44.58 - $52.6 $362,212 - $427,375	-8,125 Reduced 16.09%	42,377 $2.1 Million
Q4 2021 Feb 14, 2022	SELL	$45.82 - $56.9 $60,711 - $75,392	-1,325 Reduced 2.56%	50,502 $2.57 Million
Q3 2021 Nov 12, 2021	SELL	$43.79 - $55.78 $94,586 - $120,484	-2,160 Reduced 4.0%	51,827 $2.89 Million
Q2 2021 Aug 12, 2021	SELL	$36.86 - $44.5 $189,829 - $229,175	-5,150 Reduced 8.71%	53,987 $2.31 Million
Q1 2021 May 13, 2021	BUY	$40.32 - $50.97 $380,298 - $480,749	9,432 Added 18.98%	59,137 $2.47 Million
Q4 2020 Feb 09, 2021	BUY	$41.72 - $51.34 $25,741 - $31,676	617 Added 1.26%	49,705 $2.32 Million
Q3 2020 Nov 06, 2020	SELL	$37.02 - $51.28 $158,889 - $220,093	-4,292 Reduced 8.04%	49,088 $2.09 Million
Q2 2020 Aug 12, 2020	BUY	$43.24 - $55.02 $2,162 - $2,751	50 Added 0.09%	53,380 $2.56 Million
Q1 2020 May 11, 2020	SELL	$34.37 - $60.07 $180,098 - $314,766	-5,240 Reduced 8.95%	53,330 $2.45 Million
Q4 2019 Feb 13, 2020	SELL	$54.32 - $64.31 $108,911 - $128,941	-2,005 Reduced 3.31%	58,570 $3.52 Million
Q3 2019 Nov 12, 2019	BUY	$53.25 - $59.98 $44,517 - $50,143	836 Added 1.4%	60,575 $3.43 Million
Q2 2019 Aug 13, 2019	SELL	$46.61 - $58.45 $67,584 - $84,752	-1,450 Reduced 2.37%	59,739 $3.33 Million
Q1 2019 May 14, 2019	BUY	$38.66 - $51.82 $5,798 - $7,773	150 Added 0.25%	61,189 $3.09 Million
Q4 2018 Feb 14, 2019	SELL	$36.72 - $67.73 $393,087 - $725,049	-10,705 Reduced 14.92%	61,039 $2.46 Million
Q3 2018 Nov 13, 2018	SELL	$66.65 - $83.86 $11,663 - $14,675	-175 Reduced 0.24%	71,744 $4.97 Million
Q2 2018 Aug 13, 2018	SELL	$51.25 - $76.62 $151,187 - $226,029	-2,950 Reduced 3.94%	71,919 $5.44 Million
Q1 2018 May 15, 2018	SELL	$52.16 - $66.86 $196,121 - $251,393	-3,760 Reduced 4.78%	74,869 $3.95 Million
Q4 2017 Feb 14, 2018	BUY	$49.6 - $60.87 $349,878 - $429,376	7,054 Added 9.86%	78,629 $4.2 Million
Q3 2017 Nov 13, 2017	BUY	$46.62 - $60.36 $3.34 Million - $4.32 Million	71,575	71,575 $4.27 Million

Others Institutions Holding EGRX

# of Institutions

Shares Held

8.6M

Call Options Held

Put Options Held

100

View Full List

About EAGLE PHARMACEUTICALS, INC.

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $6.77M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

More about EGRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.

Account